Trevi Therapeutics, Inc.
TRVI
$6.47
$0.121.89%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -64.84% | -65.68% | -41.94% | -18.93% | 0.30% |
| Total Depreciation and Amortization | 19.51% | 39.81% | 85.71% | 172.55% | 186.05% |
| Total Amortization of Deferred Charges | -- | 38.79% | -3.23% | 9.40% | 9.62% |
| Total Other Non-Cash Items | 426.72% | 4,408.33% | 565.70% | 29.48% | -69.06% |
| Change in Net Operating Assets | 277.46% | 222.16% | 156.21% | 11.49% | -212.51% |
| Cash from Operations | -20.64% | -10.68% | 0.58% | -16.05% | -12.55% |
| Capital Expenditure | 74.45% | 78.35% | 73.44% | 62.96% | 13.84% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -136.08% | 1,121.38% | 205.24% | 143.24% | 155.56% |
| Cash from Investing | -136.23% | 981.54% | 203.86% | 143.06% | 155.35% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 98.67% | 98.87% | 99.03% | -11.23% | -62.94% |
| Issuance of Common Stock | 3,226.67% | 136.49% | -88.54% | -98.47% | -98.42% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 78.75% | 12.21% | 6.54% | 10.73% |
| Cash from Financing | 877.29% | 238.30% | -86.06% | -105.66% | -107.11% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -91.42% | 75.59% | 92.79% | 112.37% | 181.71% |